NCT02392572View on ClinicalTrials.gov

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 3, 2015

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Recurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic Syndrome
Interventions
DRUG

Akt/ERK Inhibitor ONC201

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Oncoceutics, Inc.
All Listed Sponsors
collaborator

Oncoceutics, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02392572 - ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter